MB-3 is a synthetic, lab-created molecule used to limit the activity of the enzyme GCN5 which reduces the accumulation of fat in heart cells that characterize arrhythmogenic cardiomyopathy – a disease that has affected young sportsmen such as Livorno soccer player Piermario Morosini and Asiago field hockey player Darcy Robinson. The discovery by a team of biologists from Eurac Research comes after several years of research in collaboration with the Medical University of Innsbruck, the Monzino Cardiology Center and the University of Milan.

Molecule identified that could counteract arrhythmogenic cardiomyopathy

Mitochondrial dysfunction in ACM pathogenesis. 

Institute for Biomedicine

Contact

News & Events

Scientific Output

Events

News

Institute's Projects

view all

Projects

Project

Research Group Projects

Related Projects

Reginald Philippe

Projects

Project

MITOACM

MAGAZINE Science Stories that Inspire

Molecule identified that could counteract arrhythmogenic cardiomyopathy

Reginald Philippe

Projects

Project

MITOACM

MAGAZINE Science Stories that Inspire

Molecule identified that could counteract arrhythmogenic cardiomyopathyself.__wrap_b(":Rjqldabjlm:",1)

Molecule identified that could counteract arrhythmogenic cardiomyopathy